[1]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55-59.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
　Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):55-59.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
点击复制

PET/CT显像在肺间质纤维化中的应用进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第1期
页码:
55-59
栏目:
出版日期:
2016-01-25

文章信息/Info

Title:
Application advancement on PET/CT in pulmonary interstitial fibrosis
作者:
张莹莹;  王振光;  孔艳
266000, 青岛大学附属医院东区PET/CT中心
Author(s):
Zhang Yingying;  Wang Zhenguang;  Kong Yan
PET/CT Center, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
关键词:
肺疾病; 间质性; 正电子发射断层显像术; 体层摄影术; X线计算机
Keywords:
Lung diseases; interstitial; Positron-emission tomography; Tomography; X-ray computed
DOI:
10.3760/cma.j.issn.1673-4114.2016.01.011
摘要:
肺间质纤维化(PIF)是一组病因各异,病理过程相似,主要累及肺间质、肺泡和细支气管的弥漫性疾病。由于该病病因多、机制复杂、治疗难,其已成为研究热点。近年来,PET/CT不仅广泛应用于肿瘤、心血管疾病及神经性疾病等方面,在PIF的早期诊断、活动判断、疗效监测和预后评价等方面也表现出独特的优势。笔者对国内外PET/CT在PIF的研究现状作一综述。
Abstract:
Pulmonary interstitial fibrosis(PIF) is a diffuse lung disease caused by different etiologies and affect interstitial tissue,alveoli and bronchiioles.PIF has the similar pathological process.Because of its diverse etiology,the complexity of the pathogenesis,treatment of difficult,PIF has became the research hotspot.Recently,PET/CT is widely used in tumor,cardiovascular disease and nervous disease,and has special advantages in earlydiagnosis,active estimate,efficacy monitoring and prognostic evaluation.This paper reviewed existing circumstances research of PET/CT in PIF at home and abroad.

参考文献/References:

[1] Cottin V,Crestani B,Valeyre D,et al.Diagnosis and management of idiopathic pulmonary fibrosis:French practical guidelines[J].Eur Respir Rev,2014,23(132):193-214.DOI:10.1183/09059180.00001814.
[2] Takimoto T,Sasada S,Yamadori T,et al.A case of adenocarcinoma of lung with idiopathic pulmonary fibrosis,showing 18-fluorodeoxyglucose uptake in positron emission tomography[J].Nihon Kokyuki Gakkai Zasshi,2005,43(4):258-262.DOI:10.1111/j.1365-2958.2008.06208.x.
[3] Meissner HH,Soo Hoo GW,Khonsary SA,et al.Idiopathic pulmonary fibrosis:evaluation with positron emission tomography[J].Respiration,2006,73(2):197-202.DOI:10.1159/000088062.
[4] Groves AM,Win T,Screaton NJ,et al.Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease:implications from initial experience with 18F-FDG PET/CT[J].J Nucl Med,2009,50(4):538-545.DOI:10.2967/jnumed.108.057901.
[5] Lambrou T,Groves AM,Erlandsson K,et al.The importance of correction for tissue fraction effects in lung PET:preliminary investigation[J].Eur J Nucl Med Mol Imaging,2011,38(12):2238-2246.DOI:10.1007/s00259-011-1906-x.
[6] Win T,Lambrou T,Hutton BF,et al.18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible:implications for future clinical trials[J].Eur J Nucl Med Mol Imaging,2012,39(3):521-528.DOI:10.1007/s00259-011-1986-7.
[7] Win T,Thomas BA,Lambrou T,et al.Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients[J].Eur J Nucl Med Mol Imaging,2014,41(2):337-342.DOI:10.1007/s00259-013-2514-8.
[8] Bondue B,Sherer F,Van SG,et al.PET/CT with 18F-FDG-and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis[J].J Nucl Med,2015,56(1):127-132.DOI:10.2967/jnumed.114.147421.
[9] El-Chemaly S,Malide D,Yao J,et al.Glucose transporter-1 distribution in fibrotic lung disease:association with[18F]-2-fluoro-2-deoxyglucose-PET scan uptake,inflammation,and neovascularization[J].Chest,2013,143(6):1685-1691.DOI:10.1378/chest.12-1359.
[10] Nusair S,Rubinstein R,Freedman NM,et al.Positron emission tomography in interstitial lung disease[J].Respirology,2007,12(6):843-847.DOI:10.1111/j.1440-1843.2007.01143.x.
[11] Fireman E,Shahar I,Shoval S,et al.Morphological and biochemical properties of alveolar fibroblasts in interstitial lung diseases[J].Lung,2001,179(2):105-117.DOI:10.1007/S004080000051.
[12] Kambouchner M,Levy P,Nicholson AG,et al.Prognostic relevance of histological variants in nonspecific interstitial pneumonia[J].Histopathology,2014,65(4):549-560.DOI:10.1111/his.12415.
[13] Tabaj GC,Fernandez CF,Sabbagh E,et al.Histopathology of the idiopathic interstitial pneumonias(ⅡP):A review[J].Respirology,2015,20(6):873-883.DOI:10.1111/resp.12551.
[14] Raghu G,Collard HR,Egan JJ,et al.An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J].Am J Respir Crit Care Med,2011,183(6):788-824.DOI:10.1164/rccm.2009-040GL.
[15] Spagnolo P,Maher TM,Richeldi L.Idiopathic pulmonary fibrosis:Recent advances on pharmacological therapy[J].Pharmacol Ther,2015,152:18-27.DOI:10.1016/j.pharmthera.2015.04.005.
[16] Umeda Y,Demura Y,Ishizaki T,et al.Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia[J].Eur J Nucl Med Mol Imaging,2009,36(7):1121-1130.DOI:10.1007/s00259-009-1069-1.
[17] Uehara T,Takeno M,Hama M,et al.Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia[J].Mod Rheumatol,2015,18:1-34.DOI:10.3109/14397595.2015.1054099.
[18] Laurent GJ.Rates of collagen synthesis in lung,skin and muscle obtained in vivo by a simplified method using[3H] proline[J].Biochem J.1982,206(3):535-544.DOI:10.1042/bj2060535.
[19] Wallace WE,Gupta NC,Hubbs AF,et al.Cis-4-[18F]fluoro-Lproline PET imaging of pulmonary fibrosis in a rabbit model[J].J Nucl Med,2002,43(3):413-420.
[20] Lavalaye J,Grutters JC,Van De Garde EM,et al.Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[(18)F]-Fluoro-L:-proline PET[J].Mol Imaging Biol,2009,11(2):123-127.DOI:10.1007/s11307-008-0164-1.
[21] Borie R,Fabre A,Prost F,et al.Activation of somatostatin receptors attenuates pulmonary fibrosis[J].Thorax,2008,63(3):251-258.DOI:10.1136/thx.2007.078006.
[22] Ambrosini V,Zompatori M,De Luca F,et al.68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis:preliminary results[J].J Nucl Med,2010,51(12):1950-1955.DOI:10.2967/jnumed.110.079962.
[23] Win T,Screaton NJ,Porter J,et al.Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose[J].Mol Imaging,2012,11(2):91-98.DOI:10.2310/7290.2011.00030.

相似文献/References:

[1]郭宵峰,刘建中,孙琦婷.肺通气/灌注平面显像与肺灌注SPECT/CT对肺栓塞诊断价值的对比性研究[J].国际放射医学核医学杂志,2015,39(4):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
　Guo Xiaofeng,Liu Jianzhong,Sun Qiting.Comparative study of pulmonary ventilation/perfusion planar imaging and pulmonary perfusion SPECT combined with low-dose CT in the diagnosis of pulmonary embolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):277.[doi:10.3760/cma.j.issn.1673-4114.2015.04.001]
[2]陆忠华,周菊英,许锡元.转化生长因子β1与放射性肺损伤[J].国际放射医学核医学杂志,2006,30(4):247.
　LU Zhong-hua,ZHOU Ju-ying,XU Xi-yuan.The effection of transforming growth factor-β1 in lung injury after radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):247.

备注/Memo

备注/Memo:
收稿日期:2015-09-07;改回日期:。
通讯作者:王振光
更新日期/Last Update: 1900-01-01